专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120220758A1 ANTIBODY HAVING ACTIVITY OF INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND USE THEREOF 失效
标题翻译：具有抑制性乙型肝炎病毒（HCV）感染的活性的抗体及其用途
公开(公告)号：US20120220758A1
公开(公告)日：2012-08-30
申请号：US13504765
申请日：2010-10-29
申请人： Takaji Wakita , Kazumi Nishimura , Noriko Nakamura , Daisuke Akazawa
发明人： Takaji Wakita , Kazumi Nishimura , Noriko Nakamura , Daisuke Akazawa
IPC分类号： C07K16/08 , C12N5/16
CPC分类号： C07K16/109 , A61K2039/505 , C07K2317/30 , C07K2317/76
摘要： An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.
摘要翻译：本发明的目的是提供抗丙型肝炎病毒（HCV）的抗体抑制感染。本发明提供一种抗丙型肝炎病毒抗体，其识别丙型肝炎病毒颗粒的构象的全部或一部分作为表位并与其结合，从而能够抑制丙型肝炎病毒与表面的结合的宿主细胞并抑制HCV感染，其人源化抗体和用于感染丙型肝炎病毒的抑制剂。

2. 发明授权

US08592559B2 Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof 失效
标题翻译：具有抑制丙型肝炎病毒（HCV）感染活性的抗体及其用途
公开(公告)号：US08592559B2
公开(公告)日：2013-11-26
申请号：US13504765
申请日：2010-10-29
申请人： Takaji Wakita , Kazumi Nishimura , Noriko Nakamura , Daisuke Akazawa
发明人： Takaji Wakita , Kazumi Nishimura , Noriko Nakamura , Daisuke Akazawa
IPC分类号： C07K16/08
CPC分类号： C07K16/109 , A61K2039/505 , C07K2317/30 , C07K2317/76
摘要： An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.
摘要翻译：本发明的目的是提供抗丙型肝炎病毒（HCV）的抗体抑制感染。本发明提供一种抗丙型肝炎病毒抗体，其识别丙型肝炎病毒颗粒的构象的全部或一部分作为表位并与其结合，从而能够抑制丙型肝炎病毒与表面的结合的宿主细胞并抑制HCV感染，其人源化抗体和用于感染丙型肝炎病毒的抑制剂。

3. 发明申请

US20100291545A1 ANTIBODY HAVING INHIBITORY ACTIVITY ON INFECTION WITH HEPATITIS C VIRUS (HCV) AND USE THEREOF 审中-公开
标题翻译：具有丙型肝炎病毒（HCV）感染的感染活动的抗体及其用途
公开(公告)号：US20100291545A1
公开(公告)日：2010-11-18
申请号：US12670383
申请日：2008-07-25
申请人： Takaji Wakita , Tetsuro Suzuki , Kenichi Morikawa , Noriaki Omi , Noriko Nakamura , Daisuke Akazawa
发明人： Takaji Wakita , Tetsuro Suzuki , Kenichi Morikawa , Noriaki Omi , Noriko Nakamura , Daisuke Akazawa
IPC分类号： C12Q1/70 , C07K16/10
CPC分类号： C07K16/109 , C07K14/005 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C12N2770/24222 , G01N2333/186
摘要： The objection of the invention is to provide an antibody that inhibits infection with hepatitis C virus (HCV). To this end, this invention provides an antibody that recognizes the hepatitis C virus (HCV) particle obtained from the hepatitis C virus (HCV) genome comprising the following (i) and (ii) ligated to each other as an antigen and has an inhibitory activity on infection with hepatitis C virus (HCV): (i) (a) the 5′-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the JFH-1 strain of the hepatitis C virus (HCV) or (b) the 5′-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the J6CF strain the hepatitis C virus (HCV); and (ii) the NS2 protein-encoding sequence, the NS3 protein-encoding sequence, the NS4A protein-encoding sequence, the NS4B protein-encoding sequence, the NS5A protein-encoding sequence, the NS5B protein-encoding sequence, and the 3′-untranslated region of the JFH-1 strain.
摘要翻译：本发明的反对是提供抑制丙型肝炎病毒（HCV）感染的抗体。为此，本发明提供一种抗体，其识别从丙型肝炎病毒（HCV）基因组获得的丙型肝炎病毒（HCV）颗粒，其包含以下（i）和（ii）作为抗原彼此连接并具有抑制性丙型肝炎病毒（HCV）感染活动：（i）（a）5'非翻译区，核心蛋白编码序列，编码E1蛋白的序列，E2蛋白编码序列和p7蛋白 - 丙型肝炎病毒（HCV）的JFH-1株的编码序列或（b）5'-非翻译区，核心蛋白编码序列，E1蛋白编码序列，E2蛋白编码序列和 J6CF株丙型肝炎病毒（HCV）的p7蛋白编码序列; 和（ii）NS2蛋白编码序列，编码NS3蛋白的序列，NS4A蛋白编码序列，NS4B蛋白编码序列，NS5A蛋白编码序列，NS5B蛋白编码序列和3' JFH-1株的非翻译区。

4. 发明申请

US20120251572A1 HEPATITIS C VIRUS VACCINE COMPOSITION 审中-公开
公开(公告)号：US20120251572A1
公开(公告)日：2012-10-04
申请号：US13499009
申请日：2010-09-30
申请人： Takaji Wakita , Masaki Moriyama , Daisuke Akazawa , Noriko Nakamura
发明人： Takaji Wakita , Masaki Moriyama , Daisuke Akazawa , Noriko Nakamura
IPC分类号： A61K39/29 , A61P37/04
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/5252 , A61K2039/5258 , A61K2039/545 , A61K2039/55505 , A61K2039/55561 , A61K2039/57 , C07K2319/30 , C12N7/00 , C12N2770/24222 , C12N2770/24223 , C12N2770/24234 , C12N2770/24263
摘要： A combination of an HCV antigen for inducing an antibody having the activity of inhibiting HCV infection and an optimum adjuvant is discovered, so as to provide an effective HCV vaccine composition. The hepatitis C virus vaccine composition comprises: inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain; an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and aluminium hydroxide.
摘要翻译：发现用于诱导具有抑制HCV感染活性的抗体的HCV抗原与最佳佐剂的组合，以提供有效的HCV疫苗组合物。丙型肝炎病毒疫苗组合物包含：通过灭活由丙型肝炎病毒基因组制备的感染性丙型肝炎病毒颗粒获得的灭活病毒颗粒，其包含编码NS3蛋白，NS4A蛋白，NS4B蛋白，NS5A蛋白和来源于丙型肝炎病毒JFH1菌株的NS5B蛋白的序列 ; 含有序列表中SEQ ID NO：5的未甲基化CpG的寡核苷酸; 和氢氧化铝。

5. 发明授权

US08604179B2 Nucleic acid comprising chimeric gene derived from hepatitis C virus 失效
标题翻译：包含源自丙型肝炎病毒的嵌合基因的核酸
公开(公告)号：US08604179B2
公开(公告)日：2013-12-10
申请号：US12989592
申请日：2009-04-24
申请人： Daisuke Akazawa , Takaji Wakita
发明人： Daisuke Akazawa , Takaji Wakita
IPC分类号： A61K39/29 , C07K14/005 , C12N7/00
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , C07K14/005 , C07K16/109 , C07K2319/00 , C12N7/00 , C12N2770/24222 , C12N2770/24234 , C12N2770/24251 , C12Q1/707 , C12Q2600/136 , C12Q2600/156
摘要： This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5′ to 3′ direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.
摘要翻译：本发明提供可用于疫苗的感染性嵌合HCV颗粒。本发明还提供了包含源自丙型肝炎病毒的嵌合基因的核酸，其包含各自编码来自除了JFH-1株之外的丙型肝炎病毒株的核心蛋白质，E1蛋白质，E2蛋白质和p7蛋白质的区域; 衍生自JFH-1株或除JFH-1株以外的丙型肝炎病毒株的NS2蛋白或源自JFH-1株的NS2蛋白的嵌合NS2蛋白和来自除JFH-1以外的丙型肝炎病毒株的NS2蛋白应变; 和NS3蛋白，NS4A蛋白，NS4B蛋白，NS5A蛋白和NS5B蛋白，其在5'至3'方向上按顺序从JFH-1菌株衍生，其中来自核心N末端的氨基酸残基的第328位脯氨酸残基蛋白质被除脯氨酸以外的氨基酸残基取代。本发明进一步提供了包含这种核酸的嵌合HCV颗粒，以及这种HCV颗粒用于疫苗的用途。

6. 发明申请

US20110045020A1 NUCLEIC ACID COMPRISING CHIMERIC GENE DERIVED FROM HEPATITIS C VIRUS 失效
标题翻译：含有从HEPATITIS C病毒中衍生的CHIMERIC基因的核酸
公开(公告)号：US20110045020A1
公开(公告)日：2011-02-24
申请号：US12989592
申请日：2009-04-24
申请人： Daisuke Akazawa , Takaji Wakita
发明人： Daisuke Akazawa , Takaji Wakita
IPC分类号： A61K39/29 , C07H21/00 , C12N15/63 , C12N7/01 , C12N5/071 , C12Q1/70 , C07K16/10 , A61P37/04 , A61P31/14
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , C07K14/005 , C07K16/109 , C07K2319/00 , C12N7/00 , C12N2770/24222 , C12N2770/24234 , C12N2770/24251 , C12Q1/707 , C12Q2600/136 , C12Q2600/156
摘要： This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5′ to 3′ direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.
摘要翻译：本发明提供可用于疫苗的感染性嵌合HCV颗粒。本发明还提供了包含源自丙型肝炎病毒的嵌合基因的核酸，其包含各自编码来自除了JFH-1株之外的丙型肝炎病毒株的核心蛋白质，E1蛋白质，E2蛋白质和p7蛋白质的区域; 衍生自JFH-1株或除JFH-1株以外的丙型肝炎病毒株的NS2蛋白或源自JFH-1株的NS2蛋白的嵌合NS2蛋白和来自除JFH-1以外的丙型肝炎病毒株的NS2蛋白应变; NS3蛋白，NS4A蛋白，NS4B蛋白，NS5A蛋白，NS5B蛋白，NS5B蛋白，5'〜3'方向顺序依次产生，其中来自核心N末端氨基酸残基的第328位脯氨酸残基蛋白质被除脯氨酸以外的氨基酸残基取代。本发明进一步提供了包含这种核酸的嵌合HCV颗粒，以及这种HCV颗粒用于疫苗的用途。

7. 发明授权

US08776927B2 Vehicle battery pack housing structure 有权
标题翻译：车载电池组件结构
公开(公告)号：US08776927B2
公开(公告)日：2014-07-15
申请号：US13701180
申请日：2011-05-23
申请人： Daisuke Akazawa , Yasutsune Terashima
发明人： Daisuke Akazawa , Yasutsune Terashima
IPC分类号： B60R16/04
CPC分类号： B60K1/04 , B21D53/88 , B60K2001/0422 , B60K2001/0433 , B60K2001/0438 , B62D25/20 , H01M2/1077 , H01M2/1083 , Y10S903/902
摘要： A vehicle battery pack housing structure includes a vehicle body panel and first, second and third panel components that define an outward-opening battery housing space. The first panel component is rigidly attached to the vehicle body panel and includes a first side wall and a base wall. The second panel component is rigidly attached to the first panel component and includes a second side wall and a first periphery wall portion. The third panel component is rigidly attached to the second panel component. The third panel component includes a second periphery wall portion that cooperates with the first periphery wall portion to form a periphery wall portion when the third panel component is rigidly attached to the second panel component.
摘要翻译：车载电池组壳体结构包括车体面板和限定外开电池容纳空间的第一，第二和第三面板部件。第一面板部件刚性地附接到车身面板并且包括第一侧壁和底壁。第二面板部件刚性地附接到第一面板部件，并且包括第二侧壁和第一周边壁部分。第三面板组件刚性地连接到第二面板组件。第三面板部件包括第二周边壁部分，当第三面板部件刚性地附接到第二面板部件时，第二周边壁部分与第一周边壁部分协作以形成周边壁部分。

8. 发明申请

US20130068548A1 VEHICLE BATTERY PACK HOUSING STRUCTURE 有权
标题翻译：车辆电池组住房结构
公开(公告)号：US20130068548A1
公开(公告)日：2013-03-21
申请号：US13701180
申请日：2011-05-23
申请人： Daisuke Akazawa , Yasutsune Terashima
发明人： Daisuke Akazawa , Yasutsune Terashima
IPC分类号： B60K1/04 , B21D53/88
CPC分类号： B60K1/04 , B21D53/88 , B60K2001/0422 , B60K2001/0433 , B60K2001/0438 , B62D25/20 , H01M2/1077 , H01M2/1083 , Y10S903/902
摘要： A vehicle battery pack housing structure includes a vehicle body panel and first, second and third panel components that define an outward-opening battery housing space. The first panel component is rigidly attached to the vehicle body panel and includes a first side wall and a base wall. The second panel component is rigidly attached to the first panel component and includes a second side wall and a first periphery wall portion. The third panel component is rigidly attached to the second panel component. The third panel component includes a second periphery wall portion that cooperates with the first periphery wall portion to form a periphery wall portion when the third panel component is rigidly attached to the second panel component.
摘要翻译：车载电池组壳体结构包括车体面板和限定外开电池容纳空间的第一，第二和第三面板部件。第一面板部件刚性地附接到车身面板并且包括第一侧壁和底壁。第二面板部件刚性地附接到第一面板部件，并且包括第二侧壁和第一周边壁部分。第三面板组件刚性地连接到第二面板组件。第三面板部件包括第二周壁部分，当第三面板组件刚性地附接到第二面板组件时，与第一周边壁部分配合形成周边壁部分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式